0
0
0
PRICED Act
12/30/2022, 12:04 AM
Summary of Bill HR 7828
The PRICED Act, also known as Bill 117 hr 7828, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to address the issue of prescription drug pricing in the United States.
The PRICED Act aims to increase transparency in the pharmaceutical industry by requiring drug manufacturers to disclose the costs associated with producing and marketing their medications. This information would then be made available to the public, allowing consumers to better understand why certain drugs are priced the way they are.
Additionally, the bill seeks to promote competition in the market by allowing for the importation of cheaper prescription drugs from other countries. This would give consumers more options when it comes to purchasing their medications and could potentially drive down prices. Furthermore, the PRICED Act includes provisions to prevent drug manufacturers from engaging in anti-competitive practices, such as pay-for-delay agreements that delay the entry of generic drugs into the market. This would help to ensure that consumers have access to affordable medications. Overall, the PRICED Act is aimed at addressing the issue of high prescription drug prices in the United States by increasing transparency, promoting competition, and preventing anti-competitive practices in the pharmaceutical industry.
The PRICED Act aims to increase transparency in the pharmaceutical industry by requiring drug manufacturers to disclose the costs associated with producing and marketing their medications. This information would then be made available to the public, allowing consumers to better understand why certain drugs are priced the way they are.
Additionally, the bill seeks to promote competition in the market by allowing for the importation of cheaper prescription drugs from other countries. This would give consumers more options when it comes to purchasing their medications and could potentially drive down prices. Furthermore, the PRICED Act includes provisions to prevent drug manufacturers from engaging in anti-competitive practices, such as pay-for-delay agreements that delay the entry of generic drugs into the market. This would help to ensure that consumers have access to affordable medications. Overall, the PRICED Act is aimed at addressing the issue of high prescription drug prices in the United States by increasing transparency, promoting competition, and preventing anti-competitive practices in the pharmaceutical industry.
Congressional Summary of HR 7828
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
Read the Full Bill
Current Status of Bill HR 7828
Bill HR 7828 is currently in the status of Bill Introduced since May 18, 2022. Bill HR 7828 was introduced during Congress 117 and was introduced to the House on May 18, 2022. Bill HR 7828's most recent activity was Referred to the House Committee on Energy and Commerce. as of May 18, 2022
Bipartisan Support of Bill HR 7828
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
20Democrat Cosponsors
18Republican Cosponsors
2Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 7828
Primary Policy Focus
HealthAlternate Title(s) of Bill HR 7828
PRICED Act
PRICED Act
Price Relief, Innovation, and Competition for Essential Drugs Act
To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.
Comments
Sponsors and Cosponsors of HR 7828
Latest Bills
Ending Importation of Russian Oil Act
Bill HR 6968March 11, 2026
HONOR Act
Bill S 327March 11, 2026
Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes.
Bill HR 7147March 11, 2026
A bill to prohibit the Department of Homeland Security from constructing, acquiring, renovating, or operating any new processing site or detention center without providing a mechanism for public comments regarding such activity, entering into a signed, written agreement with appropriate State and local officials, and providing Congress with advance notice of such activity.
Bill S 3894March 11, 2026
A bill to amend title 10, United States Code, to authorize representatives of veterans service organizations to participate in presentations to promote certain benefits available to veterans during preseparation counseling under the Transition Assistance Program of the Department of Defense, and for other purposes.
Bill S 3938March 11, 2026
A bill to amend the Elementary and Secondary Education Act of 1965 to expand access to school-wide arts and music programs, and for other purposes.
Bill S 4018March 11, 2026
A bill to allow States to require payment of State fees related to boating as a condition for issuance of a vessel number and to collect such fees in conjunction with other fees related to vessel numbering.
Bill S 3985March 11, 2026
A bill to restore competition in the meatpacking industry by reducing excessive concentration and market power and ultimately reduce prices for American consumers, and for other purposes.
Bill S 4007March 11, 2026
A resolution requesting information on the Republic of Guatemala's human rights practices pursuant to section 502B(c) of the Foreign Assistance Act of 1961.
Bill SRES 636March 11, 2026
A bill to amend the Internal Revenue Code of 1986 to increase the standard deduction, and for other purposes.
Bill S 4042March 11, 2026
Fair Care Act of 2022
Bill HR 8588March 8, 2023




